-transparent.png){kind=logo}
Twenty-four parkinsonian patients compared pergolide and bromocriptine therapy in a randomized double-blind, two-period crossover study. Both drugs were adjusted to an optimal balance between benefits and side effects. The mean daily dose and dose range for pergolide and bromocriptine were 3.3 mg (0.7 to 7.2) and 42.7 mg (5.8 to 87.5), respectively. Adjunctive medications, which for most patients included levodopa (plus carbidopa), were not altered during the study. A similar spectrum of clinical effects was found with both drugs and with lisuride, which was used to treat 13 of the patients in a previous study. Despite neurochemical differences in the antiparkinsonian ergots, their clinical utility is quite similar. We draw attention to hepatotoxicity and pleural reactions that may occur rarely with these drugs.
P A LeWitt, and
C D Ward, and
T A Larsen, and
M I Raphaelson, and
R P Newman, and
N Foster, and
J M Dambrosia, and
D B Calne
February 1984,
Neurology,
P A LeWitt, and
C D Ward, and
T A Larsen, and
M I Raphaelson, and
R P Newman, and
N Foster, and
J M Dambrosia, and
D B Calne
April 1978,
Annals of neurology,
P A LeWitt, and
C D Ward, and
T A Larsen, and
M I Raphaelson, and
R P Newman, and
N Foster, and
J M Dambrosia, and
D B Calne
January 1983,
Advances in neurology,
P A LeWitt, and
C D Ward, and
T A Larsen, and
M I Raphaelson, and
R P Newman, and
N Foster, and
J M Dambrosia, and
D B Calne
January 1978,
Journal of neural transmission,
P A LeWitt, and
C D Ward, and
T A Larsen, and
M I Raphaelson, and
R P Newman, and
N Foster, and
J M Dambrosia, and
D B Calne
May 1985,
Neurology,
P A LeWitt, and
C D Ward, and
T A Larsen, and
M I Raphaelson, and
R P Newman, and
N Foster, and
J M Dambrosia, and
D B Calne
June 1978,
The New Zealand medical journal,
P A LeWitt, and
C D Ward, and
T A Larsen, and
M I Raphaelson, and
R P Newman, and
N Foster, and
J M Dambrosia, and
D B Calne
July 1976,
British medical journal,
P A LeWitt, and
C D Ward, and
T A Larsen, and
M I Raphaelson, and
R P Newman, and
N Foster, and
J M Dambrosia, and
D B Calne
August 1976,
Lancet (London, England),
P A LeWitt, and
C D Ward, and
T A Larsen, and
M I Raphaelson, and
R P Newman, and
N Foster, and
J M Dambrosia, and
D B Calne
May 1978,
British medical journal,
P A LeWitt, and
C D Ward, and
T A Larsen, and
M I Raphaelson, and
R P Newman, and
N Foster, and
J M Dambrosia, and
D B Calne
November 1974,
British medical journal,
